Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Flagstar Bank NA (FLG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Flagstar Bank NA — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Flagstar Bank NA trades at $14.46 (market cap $6.15B). The key difference: Flagstar Bank NA is the larger of the two by market cap, and Flagstar Bank NA pays a 0.27% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FLG | |
|---|---|---|
Market Cap | $4.49B | $6.15B |
Sector | Health | Financials |
52-Week High | $28.06 | $15.28 |
52-Week Low | $20.06 | $10.72 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Flagstar Bank (FLG) trades at $14.84, up 1.71% today, showing technical bullish momentum with strong moving average signals. The company has delivered two consecutive quarterly earnings beats (Q4 2025 and Q1 2026) and recently announced a proprietary technology transformation. Despite negative profitability metrics, the stock trades below book value (P/B 0.81) and analysts maintain a 50/50 buy/hold split with a $16.94 consensus target.
FLG presents a turnaround story with improving fundamentals but carries execution risks. The bank's shift toward profitability and technology investments offers potential upside, though negative margins and high interest expenses remain concerns. With the current price below analyst targets, the stock offers value potential but requires careful monitoring of credit quality and operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
